AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2020
Price : $35 *
At a glance
- Drugs Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms RAINBOWFISH
- Sponsors Roche
- 02 Oct 2019 According to a PTC Therapeutics media release, first patient was enrolled in this trial in August 2019.
- 23 Sep 2019 Planned End Date changed from 14 Jun 2025 to 8 Oct 2025.
- 30 May 2019 Planned End Date changed from 15 Mar 2025 to 14 Jun 2025.